Sijibio Collaborates with US WFIRM on 3D Printing-Based Bone and Cartilage Regeneration Research

Process of fabricating osteochondral tissue using 3D printing.

[Asia Economy Reporter Lee Gwan-joo] Sijibio announced on the 10th that it will collaborate with the Wake Forest Institute for Regenerative Medicine (WFIRM) in the United States to advance global regenerative medicine research.

Sijibio will conduct joint research with Professor Lee Sang-jin's research team at WFIRM, a leading group in 3D bioprinting, on regenerative treatment of joints through the shaping of bone-cartilage composite structures.

To shape the bone-cartilage composite tissue structure, Sijibio plans to supply its self-developed high-precision multi-channel 3D bioprinter and bio-materials such as bioactive glass ceramic (BGS-7), recombinant human bone morphogenetic protein-2 (rhBMP-2), and transforming growth factor-beta 3 (TGF-β3) to Professor Lee's research team. The research team will fabricate 3D-shaped scaffolds using the 3D printer that allow bone cells and cartilage cells to grow together, and study technologies to differentiate and regulate them into bone and cartilage using the bio-materials.

Yoo Hyun-seung, CEO of Sijibio, said, "We hope this research will open the way for joint regenerative treatment and improve the quality of life for many patients with joint damage. Based on cooperation with WFIRM, which has world-class research capabilities, we will strive to become a global leader in the joint treatment market by developing differentiated products that overcome the limitations of existing treatment methods."

This content was produced with the assistance of AI translation services.